Pharmacy Times

JULY 15, 2025

Immune effector cell–associated neurotoxicity syndrome was less common but observed in 28% (grade ≥3, 5%). 2025029274 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Doi:10.1182/blood.2025029274 Subscribe Now!

Pharmacy Technician 29

Pharmacy Technician Immunization Immunity Compounding Pharmacies 29

Pharmacy Times

JULY 14, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Independent Pharmacies 51

Independent Pharmacies Pharmacy Technician Compounding Pharmacies Hospitals 51

Pharmacy Times

JULY 7, 2025

1 DOORwaY 90 Study Results The approval was supported by data from the prospective, multicenter, open-label, single-arm DOORwaY 90 study that evaluated the safety and efficacy of Y-90 resin microspheres in individuals with unresectable HCC.

Pharmacy Technician 20

Pharmacy Technician Compounding Pharmacies Diabetes Pharmacy Management 20

Pharmacy Times

JULY 22, 2025

This change mirrored a January 2025 FDA safety alert and label update that urged providers to consider genetic testing, inform patients of the risks, and discuss available options.

Pharmacy Technician 20

Pharmacy Technician Insurance Coverage and Processing Compounding Pharmacies Diabetes 20

Pharmacy Times

JUNE 16, 2025

1 As part of another action designed to reduce drug costs, Newsom also announced the expansion of CalRx, the state’s initiative to produce generic drugs under the state’s own label, giving CalRx the authority to purchase brand-name drugs. Furthermore, DMHC would have clear authority to enforce rules and penalize violations.

Pharmacy Technician 26

Pharmacy Technician Drug Pricing Insurance Coverage and Processing Compounding Pharmacies 26

Pharmacy Times

JULY 17, 2025

1 Image Credit: Syahrir | stock.adobe.com Gabapentin is FDA approved for partial seizures and postherpetic neuralgia, but has widespread off-label use for various chronic pain conditions, including back pain.

Pharmacy Technician 55

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 55

Pharmacy Times

JUNE 20, 2025

Oncology pharmacy practice changes at a rapid pace. There are too many drug approvals, label updates, and new data published for even the most skilled and experienced oncology pharmacist to keep up with, let alone those still building their baseline knowledge. Fifteen years ago, pharmacists could learn oncology on the job.

Pharmacy Technician 46

Pharmacy Technician Compounding Compounding Pharmacies Biosimilars 46

Pharmacy Times

JULY 2, 2025

2,4 The open-label, single-arm, multicenter, multidose study enrolled 86 patients with CKD and hyperphosphatemia receiving maintenance hemodialysis. The trial’s primary objective was to evaluate the tolerability of OLC at its clinically effective doses (goal: serum phosphate ≤ 5.5

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Adverse Reactions 29

Pharmacy Times

JULY 10, 2025

Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)

Pharmacy Technician 26

Pharmacy Technician Immunization Immunity Specialty Pharmacies 26

Pharmacy Times

JULY 15, 2025

What we've done is blend PillPack's innovative packaging with Amazon Pharmacy's user-friendly approach and affordability, so these patients can now get their medications in convenient, personalized packets and order everything online through our digital pharmacy.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Pharmacies Biosimilars 26

Pharmacy Times

JUNE 9, 2025

These conclusions were presented as part of an abstract from the open-label, phase 3 CheckMate 816 trial (NCT02998528) at the 2025 American Society of Clinical Oncology Annual Meeting in Chicago, Illinois, and subsequently published in the Journal of Clinical Oncology.

Chemotherapy 26

Chemotherapy Pharmacy Technician Immunization Immunity 26

Pharmacy Times

JULY 7, 2025

Limitations included open-label design and dosage constraints, but the multicountry approach enhanced generalizability and external validity. 1 “The limitations of this study were it being open-label, allowing potential assessment biases and the absence of blinded assessment of clinical endpoints. Additionally, SOCs with at least 2.5%

Pharmacy Technician 39

Pharmacy Technician Compounding Pharmacies Dosage Diabetes 39

Pharmacy Times

JUNE 5, 2025

Detect-A-Dose lid-label cover enhances medication recognition, reducing packaging errors through a contrasting visual pattern. 1-3 Detect-A-Dose Lid Label Covers. 4 Detect-A-Dose features a contrasting black and white pattern on the underside of its label to make missing doses for patients apparent to pharmacists.

Pharmacy Technician 26

Pharmacy Technician Packaging Labelling Immunization 26

Pharmacy Times

JUNE 23, 2025

Along with the successful pivotal trials, Launch-HTN and Advance-HTN, and the ongoing open-label extension trial, these results comprise the core package for our planned NDA submission.” Explore-CKD established that lorundrostat 25 mg once daily has a favorable clinical profile for this patient population.

Pharmacy Technician 51

Pharmacy Technician Diabetes Compounding Pharmacies Pharmacy Management 51

Pharmacy Times

JUNE 30, 2025

2-5 In the multicenter, phase 2, open-label prospective study, researchers investigated ropeg-IFN-α2b treatment in patients with profibrotic MF or DIPSS low-intermediate-1 risk MF. With phase 3 trial win, PharmaEssentia plots label expansion for rare blood cancer treatment Besremi. Updated November 30, 2023. Accessed June 30, 2025.

Pharmacy Technician 34

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 34

Pharmacy Times

JULY 3, 2025

Typically, it's a white-labeled experience, so it has the look and feel of that digital therapeutic throughout the entire experience. Pharmacy Times : What is the future role of pharmacists as digital prescriptions become standard care?

Pharmacy Technician 32

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 32

Pharmacy Times

JULY 18, 2025

It has 1 region that binds to CD3, a protein on T cells, a type of immune cell, and 2 regions that bind to CD20, a protein on B cells, which can either be healthy or malignant. Events that were considered consistent with immune effector cell-associated neurotoxicity syndrome occurred in 4 patients, all of which were concurrent with CRS.

Pharmacy Technician 26

Pharmacy Technician Immunization Immunity Compounding Pharmacies 26

Pharmacy Times

JUNE 23, 2025

1 Image credit: Cynthia | stock.adobe.com The discussion featured Vivian Fonseca, MD, of the Tulane University School of Medicine, who presented an overview of tirzepatide based on the FDA-approved label and clinical guidelines. He was joined by Laura, a patient who began tirzepatide treatment shortly after being diagnosed with T2D.

Diabetes 32

Diabetes HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies 32

Pharmacy Times

JUNE 11, 2025

Its efficacy was evaluated in the 2 multicenter, single-arm open-label phase 2 clinical trials TRUST-I (NCT04395677) 3 and TRUST-II (NCT04919811). Taletrectinib is an oral, potent, central nervous system (CNS)–active, selective, next generation ROS1 inhibitor approved for the treatment of adults with advanced ROS1+ NSCLC.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 29

Pharmacy Times

JUNE 9, 2025

2 However, Dalton noted that some procedures can change once a treatment is FDA-approved, with complications from Risk Evaluation and Mitigation Strategy programs as well as the occasional surprise on an FDA label. But doing so requires a new kind of expertise that spans science, strategy, and systems thinking.

Pharmacy Technician 22

Pharmacy Technician Compounding Pharmacies Pharmacy Management Hospitals 22

Pharmacy Times

JUNE 12, 2025

Primary chemoablation of recurrent low-grade intermediate-risk nonmuscle-invasive bladder cancer with UGN-102: A single-arm, open-label, phase 3 trial (ENVISION). Prasad SM, Shishkov D, Mihaylov NV, et al. February 1, 2025. doi:10.1097/JU.0000000000004296 0000000000004296 4.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 26

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older.

Labelling 26

Labelling Pharmacy Technician Independent Pharmacies Compounding Pharmacies 26

Pharmacy Times

JUNE 9, 2025

3 neoCARHP was a multicenter, open-label, randomized, noninferiority phase 3 trial (NCT04858529) that compared the efficacy and safety of TCbHP with THP in the neoadjuvant setting. If caught early, the cancer can often be treated and cured, according to Cleveland Clinic. Gao HF, Li W, Wu Z, et al. J Clin Oncol. doi:10.1200/JCO.2025.43.17_suppl.LBA500

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Hospitals Pharmacy Management 26

Pharmacy Times

JUNE 30, 2025

2,3 LIMBER is a phase 1, open-label, dose escalation study evaluating INCB057643 as a monotherapy at a dose escalation of 4 to 12 mg daily (part 1) or in combination with ruxolitinib at a dosage of 4 mg once daily and escalating to the maximum tolerated dose in part 1 (part 2).

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 26

Pharmacy Times

JUNE 20, 2025

In general, choosing a product that has broad spectrum on the label, covering both UV-A and UV-B rays and containing 20% zinc oxide, for her children will be optimal, especially for more sensitive areas of the skin. Whereas SPF 15 blocks approximately 93% of UV-B rays, SPF 30 and SPF 50 increase coverage slightly (97% and 98%, respectively).

Pharmacy Technician 39

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 39

Pharmacy Times

JUNE 11, 2025

1,2 Image Credit: © stockdevil - stock.adobe.com Results from 2 single-dose, open-label, randomized phase 1 crossover studies of healthy adults served as the basis for this approval. These trials were designed to establish bioequivalence between zanubrutinib capsules and zanubrutinib tablets.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 29

Pharmacy Times

JUNE 9, 2025

months versus 2.1 The findings were presented at the 2025 American Society of Clinical Oncology Annual Meeting, which was held in Chicago, Illinois. It is the first PROTAC to be evaluated in a phase 3 clinical trial, according to the investigators.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 29

Pharmacy Times

JUNE 12, 2025

Molecular model of pembrolizumab | Image Credit: © Dr_Microbe - stock.adobe.com The FDA’s decision was based on data from the randomized, multicenter, open-label KEYNOTE-689 trial (NCT02358031). This marks the first FDA approval for a perioperative treatment approach in locally advanced HNSCC.

Pharmacy Technician 32

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 32

Pharmacy Times

JUNE 15, 2025

In the randomized, open-label, multicenter phase 3 NATALEE clinical trial (NCT05306340), ribociclib (Kisqali; Novartis) plus endocrine therapy, a nonsteroidal aromatase inhibitor (NSAI), significantly improved invasive disease-free survival among individuals with HR-positive (HR+) and HER2-negative (HER2-) early breast cancer.

Pharmacy Technician 42

Pharmacy Technician Mayo Clinic Compounding Pharmacies Pharmacy Management 42

Pharmacy Times

JULY 1, 2025

Recent research shows that an individual’s mental state can directly affect bodily functions, and learning through association can change immune and hormonal responses in the body. 1 Image credit: Maryna | stock.adobe.com The brain and body are interconnected and constantly influence each other to maintain homeostasis.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Immunization 26

Pharmacy Times

JUNE 23, 2025

In 2024, the FDA granted datopotamab a breakthrough therapy designation for patients with NSCLC based on data from the TROPION-Lung05 and TROPION-Lung01 trials that have since led to the agent’s accelerated approval.

Pharmacy Technician 34

Pharmacy Technician Compounding Pharmacies Diabetes Chemotherapy 34

Pharmacy Times

JULY 21, 2025

" 1 ALKAZAR is a global, randomized, controlled, open-label phase 3 trial studying neladalkib in TKI-naïve patients with advanced ALK-positive NSCLC. About 450 patients will be enrolled and randomly assigned to receive either 150 mg of neladalkib orally once per day or 600 mg of alectinib (Alecensa; Genentech) orally twice per day.

Pharmacy Technician 20

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 20

Pharmacy Times

JULY 14, 2025

SHOW MORE The expanded instructions for use labeling expand on the Farawave and Farawave Nav Pulsed Field Ablation (PFA) catheters. The update aims to enhance AF treatment with safe, effective ablation technologies, with future trials planned for more complex arrhythmias.

Labelling 26

Labelling Pharmacy Technician Compounding Pharmacies Hospitals 26

BioPharma Dive

JULY 22, 2025

Ned Pagliarulo Johnson & Johnson on Monday asked the FDA to approve a new immune disease drug called icotrokinra that it and Protagonist Therapeutics developed for moderate-to-severe plaque psoriasis. The company is also studying icotrokinra in ulcerative colitis and other immune diseases mediated by IL-23. — and Europe.

Specialty Pharmacies 60

Specialty Pharmacies Drug Pricing Drug Development Labelling 60

Fusion Pharmacy

MAY 31, 2022

Stress can weaken your immune system, making you more susceptible to colds and other illnesses. Supplements can help strengthen your immune system. Supplements do not require a prescription to obtain – you can buy them over the counter at a drugstore or pharmacy. Supplements can help improve your focus and memory.

Specialty Pharmacies 52

Specialty Pharmacies Immunization Immunity Labelling 52